Search results

Selected filters:

Life Sciences

Article type




600 results found for your search

Sort options

Jarrod Ward (Strategy 300)

Ahurei Pty Ltd

Ahurei Pty Ltd provides commercial and strategic advice for businesses looking to put their intellectual property to work. Ahurei also provides in-house IP management solutions to bridge the gap betwe...

Mark Kokes (Strategy 300)

NantWorks, LLC

Mark Kokes is chief IP officer at NantWorks, LLC and the Nant family of companies, a large healthcare conglomerate based in Los Angeles. The Nant family is comprised of numerous companies which p...

Nobuo Tanaka (Strategy 300)

Yokogawa Electric Corporation

Nobuo Tanaka has been an IP expert at Yokogawa Electric Corporation since April 2019. He is responsible for all of the company’s IP-related activities, including patent prosecution, licensin...
01 December 2016

<strong>IP lawyer:</strong> Amped-up protection on the cards for recombinant DNA products

Australian patent authorities continue to wrestle with the treatment of gene-related inventions. A new ruling may extend the life of patents covering medicines made with recombinant DNA technology

25 May 2018

Protecting second medical use – opportunities and pitfalls

Innovators continue to develop drugs to further understand how to optimise the use of known drugs.

25 May 2018

Sprycel – new plausibility threshold for life sciences patents?

The Technical Board of Appeal of the European Patent Office (EPO) decision (February 1 2017) upholding the revocation of Bristol-Myer Squibb’s (BMS) European Patent 1169038 for lack of inventive step came as a shock and a surprise for many in the pharmaceutical sector.

31 March 2019

The owners of the biggest patent portfolios in the United States revealed

The IAM/ktMINE Patent 100 is back to give the latest rundown on the companies that own the largest patent portfolios in the United States. While Samsung retains a vice-like grip on the top spot, there is much to analyse further down the rankings as we see new players entering the 100, different sectors doubling down on their patenting efforts and some notable fallers.

31 March 2019

The ITC as a forum for biologic and biosimilar patent disputes

While disputes brought before the International Trade Commission relating to biologics and biosimilar patents are rare, there is a growing case for why rights holders in this sector should consider the commission as part of their litigation strategy.

30 January 2019

<em>Arrow</em> declarations: exploiting court flexibility to clear a path to market

When it comes to litigation strategy, drug businesses have another option to consider in some cases thanks to recent rulings from the courts of England and Wales.

31 January 2019

Critical condition: why patents matter more than ever for medical devices

From uncertainty over patent eligibility to the forces of convergence increasingly shaping the sector, IP strategy has never been more important for medical device companies.

23 May 2019

Benevolent despot or tyrant? <em>Alice v CLS Bank</em> five years on

In the five years since the US Supreme Court’s decision in Alice Corp v CLS Bank International, patent owners, their advisers, the judiciary and legislators have all struggled to come to terms with its impact. With policymakers currently eyeing possible legislation on Section 101 of the US Patent Statute, the case continues to cast a long shadow on the IP market.

24 May 2019

The 1,000 Club: lifting the lid on the IP-owning elite

The IAM/ktMINE US Patent 1,000 counts down every entity that owns at least 1,000 US grants, with breakdowns by country and industry, to reveal the biggest movers.

30 August 2019

Why start-ups should get serious about patent protection

Only a small percentage of the world’s tech start-ups develop a patent portfolio of any depth, but failure to align IP strategy with long-term business objectives could cost companies millions down the line in litigation and licensing fees

25 May 2018

SPC system – simple, transparent and easy to apply?

Patent term extensions for human and veterinary medicaments and plant protection products are available in Europe through the grant of supplementary protection certificates (SPCs), which effectively extend the term of a granted patent in relation to a particular product that is the subject of a marketing authorisation.

30 March 2018

China’s biggest public research body holds public patent auction, showing it will focus relentlessly on monetisation

Last week, the Chinese Academy of Sciences (CAS) held its first public patent auction, which saw a selection of 932 patents go under the gavel. The rights were listed online roughly two weeks prior to the 21st March sale. In the event, the most…